Somapacitan
Also referenced as: Sogroya
A long-acting albumin-binding growth-hormone analogue used for defined growth and GH-deficiency indications.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
The February 2026 Sogroya label includes adult GH deficiency, pediatric indications from age 2.5 including GHD and specified SGA, Noonan and idiopathic-short-stature criteria; read the exact label.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A long-acting albumin-binding growth-hormone analogue used for defined growth and GH-deficiency indications.
The February 2026 Sogroya label includes adult GH deficiency, pediatric indications from age 2.5 including GHD and specified SGA, Noonan and idiopathic-short-stature criteria; read the exact label.
It supplies a GH analogue directly; it is not a peptide signal that asks the pituitary to release endogenous GH.
Why It's Being Studied
- Growth hormone deficiency
- Pediatric growth disorders
Mechanism of Action
It activates GH receptors and increases downstream IGF-1, unlike secretagogues that stimulate pituitary GH release.
It activates GH receptors and increases downstream IGF-1, unlike secretagogues that stimulate pituitary GH release. It supplies a GH analogue directly; it is not a peptide signal that asks the pituitary to release endogenous GH.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Growth hormone deficiency
- Pediatric growth disorders
- Subcutaneous approved medicine
Evidence Summary
Randomized and registrational studies support labeled growth responses in eligible populations.
Higher tiers carry more weight. Filled tiers have evidence for Somapacitan; tap to read it.
- Randomized and registrational studies support labeled growth responses in eligible populations.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized and registrational studies support labeled growth responses in eligible populations.
Reported Adverse Events in Research
- Glucose intolerance, edema, intracranial hypertension and neoplasia precautions are important.
Limitations of Current Evidence
- It supplies a GH analogue directly; it is not a peptide signal that asks the pituitary to release endogenous GH.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Somapacitan | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Somapacitan — prescribing label